

ASCO-2011 – RG7204 Vs Ipilimumab : The first line Dilemma persists

<https://marketpublishers.com/r/A5D1CFEBCB8EN.html>

Date: June 2011

Pages: 2

Price: US\$ 140.00 (Single User License)

ID: A5D1CFEBCB8EN

Abstracts

ROG and BMJ announced the detailed data from phase III pivotal studies on RG7204 and ipilimumab respectively. With the overall survival data on the two drugs more or less comparable, physician is likely to weigh ipilimumab's superior durability of response compared to RG7204 (19.3m vs 6.7m) on one side with its inferior toxicity profile (56% vs 10% ? Grade 3 safety events) on the other side for deciding on the first line treatment option. Emergence of biomarkers for predicting ipilimumab response would be crucial for resolving this dilemma. Retrospective analysis of clinical trials shows the absolute lymphocyte count is a strong proxy for predicting durability of response with ipilimumab.

Contents

COMPANIES MENTIONED

Roche, Bristol Myers Squibb, Daiichi Sankyo, ROG, BMY, 4568

I would like to order

Product name: ASCO-2011 – RG7204 Vs Ipilimumab : The first line Dilemma persists

Product link: <https://marketpublishers.com/r/A5D1CFEBCB8EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5D1CFEBCB8EN.html>